Inserm
U 1995
EDUCATION AND TRAINING 2005 PhD in Molecular Medicine, Faculty of Medicine and Surgery, University of Milan, Milan (Italy) 1999 Master in Biological Sciences, Faculty of Biological Sciences, University of Milan, Milan (Italy) POSITIONS/RESEARCH EXPERIENCE 2013-Present Senior Researcher in Neuroscience, Institute Baulieu, U1195 Inserm, Paris-Saclay University, Le Kremlin Bicêtre (France) 2011-2013 Researcher in Neuroscience, Dept of Experimental Medical Sciences, Lund University, Lund (Sweden) 2010-2011 Assistant Professor of Neuroscience, Dept of Neurology and Neuroscience, Weill Cornell Medicine, New York (USA) 2007-2010 Instructor in Neuroscience, Dept of Neurology and Neuroscience, Weill Cornell Medicine, New York (USA) 2005-2007 Post-doctoral Associate in Neuroscience, Dept of Neurology and Neuroscience, Weill Cornell Medicine, New York (USA) SCIENTIFIC EVALUATION ACTIVITIES *Grant ad hoc Reviewer - Alzheimer’s Association (USA) - European Research Executive Agency (REA) - Association of British Neurologists (ABN) - French National Research Agency (ANR) PUBLICATIONS Articles 1. Klionsky DJ,..., Tampellini D et al. (2021) Guidelines for the use and interpretation of assays for moni-toring autophagy. Autophagy. Feb 8:1-382. doi: 10.1080/15548627.2020.1797280. 2. Akwa Y, Gondard E, Mann A, Capetillo-Zarate E, Alberdi E, Matute C, Marty S, Vaccari T, Lozano AM, Baulieu EE, Tampellini D (2018) Synaptic activity protects against AD and FTD-like pathology via autophagic-lysosomal degradation. Mol. Psychiatry 23(6): 1530-1540 3. Mann A, Gondard E, Tampellini D, Milsted JAT, Marillac D, Hamani C, Kalia SK, Lozano AM (2018) Chronic deep brain stimulation in an Alzheimer’s disease mouse model enhances memory and reduces pathological hallmarks Brain Stimul. 11(2): 435-444. Tampellini D, Rahman N, Lin MT, Capetillo-Zarate E and Gouras GK (2011) Impaired β-amyloid secretion in Alzheimer's disease pathogenesis. J. Neurosci., 31(43):15384-15390 4. Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT and Gouras GK (2010) Effects of synaptic modulation on β-amyloid, synaptophysin and memory performance in Alzheimer’s disease transgenic mice. J. Neurosci. 30(43): 14299-14304 5. Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E, Ma T, Zheng R, Lu B, Nanus DM, Lin MT and Gouras GK (2009) Synaptic activity reduces intraneuronal β-amyloid, promotes APP transport to synapses and protects against β-amyloid -related synaptic alterations. J. Neurosci. 29(31): 9704-9713 Reviews 1. Tampellini D (2015) Synaptic activity and Alzheimer’s disease: a critical update. Front. Neurosci. 9(423): 1-7 2. Tampellini D and Gouras GK (2010) Synapses, synaptic activity and intraneuronal Aβ in Alzheimer’s disease. Front. Aging Neurosci. 2(13): 1-5 Book chapters 1. Tampellini D and Gouras GK (2011) Analysis of vesicular trafficking in primary neurons by live-imaging. Methods Mol. Biol. 793: 343-350

Presenter of 1 Presentation

PROTECTIVE EFFECTS OF SYNAPTIC STIMULATION BY PATHOLOGIC TAU CLEARANCE IN AD AND PD

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
08:30 AM - 10:30 AM
Room
ONSITE: 112
Lecture Time
10:00 AM - 10:15 AM

Abstract

Aims

Objectives

Loss of synapses and alterations of synaptic plasticity are central events in Alzheimer’s disease (AD) and Parkinson’s disease (PD) pathogenesis; and they are associated with progressive accumulation of tau protein. Recent studies demonstrated protective effects of neuronal/synaptic activation, via deep brain stimulation (DBS) or other means, in model of AD and PD, including reduction of pathological tau and neuroprotection. We have found that synaptic stimulation enhanced auto-lysosomal degradation of pathologic tau protecting synapses (Akwa et al., 2018).

Currently, we are exploring the cellular mechanism(s) responsible for such positive outcomes. Recently, we have found the involvement of transcription factor EB (TFEB), a master regulator of autophagy and lysosomal proteins, in tau clearance upon stimulation.

Methods

Synaptic activity was induced by electrode implantation in the entorhinal cortex of 3xTg mice, or chemically in primary neurons prepared from tau mice PS19. Data of DBS treatment were confirmed in PD patients who underwent DBS. We performed RT-qPCR, live imaging, biochemical and histological analyses and relative statistical analyses.

Results

DBS reduced levels of pathological tau in 3xTg mice. Data were confirmed in DBS-treated PD patients. Tau clearance required lysosmal activity, which was enhanced by DBS. TFEB activation was also trigger by stimulation, and RT-qPCR analyses revealed increased transcription of TFEB downstream genes, including lysosomal ATP6-V1H, ATP6-V0D1, in neurons.

Conclusions

DBS reduces levels of pathologic tau in models of AD and PD brains. In addition, we found that at cellular and molecular level synaptic activity enhances lysosomal degradation and triggers TFEB inducing the transcription of its downstream genes.

Hide